FAPI Development2021-05-21T17:56:07+00:00



SOFIE licensed a family of theranostic compounds that target the tumor stroma from the University of Heidelberg, the team that invented PSMA-617 (Novartis). The FAPI compounds inhibit the fibroblast activation protein, which is an important cancer target. Over 500 patients have been imaged to date with the diagnostic compound and initial therapeutic studies are underway. FAPI received the Product/Image/Publication of the Year Award at the Society for Nuclear Medicine and Molecular Imaging.

“FAPI is opening new doors in nuclear medicine, not only in imaging but also in theranostics.”

Dr. Frederick Giesel, M.D, M.B.A.
Universität Heidelberg · Nuclear Medicine


Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging

Christian Schmidkonz 1, Simon Rauber 2, Armin Atzinger 1, Rahul Agarwal 2, Theresa Ida Götz 1, Alina Soare 2, Michael Cordes 1, Olaf Prante 1, Christina Bergmann 2, Arnd Kleyer 2, Philipp Ritt 1, Simone Maschauer 1, Peter Hennig 1, Johannes Toms 1, Markus Köhner 1, Bernhard Manger 2, John H Stone 3, Uwe Haberkorn 4, Tobias Baeuerle 5, Jörg H W Distler 2, Abbas Agaimy 6, Torsten Kuwert 1, Georg Schett 2, Andreas Ramming 7 Objectives: To date, there is no valuable tool to assess fibrotic disease activity in humans in [...]

November 5th, 2020|Publications|

Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers?

Patrick Conen 1 2, Felix M Mottaghy 3 4 5 Purpose: Cancer-associated fibroblasts (CAFs) expressing fibroblast activation protein (FAP) have been associated with the aggressive nature of head and neck cancers (HNCs). These tumours grow diffusely, leading to extremely challenging differentiation between tumour and healthy tissue. This analysis aims to introduce [...]

November 4th, 2020|Publications|

68Ga-FAPI PET/CT in Assessment of Liver Nodules in a Cirrhotic Patient

Liang Zhao 1, Jianwei Gu 2, Kaili Fu 1, Qin Lin 1, Haojun Chen 2 Abstract: Ga-FAPI PET/CT was performed in a 56-year-old cirrhotic patient with multiple liver nodules, which were suspected of hepatocellular carcinoma by contrast-enhanced magnetic resonance but were not visualized by F-FDG PET/CT. Increased Ga-FAPI liver uptake was observed in [...]

October 3rd, 2020|Publications|


Guided by our Scientific Advisory Board, sanctioned peer-reviewed publications, and our own FAPI development plan, we remain committed to the process of making FAPI precursor material and radiolabeled compounds readily available.


Are you a hospital or clinic interested in participating in our clinical trial? Following the filing of its IND, we will be launching a FAPI-based clinical trial. We expect to collaborate to achieve the required designed endpoints.


Are you an academic researcher interested in evaluating the FAPI compounds within the preclinical and clinical space for both mainstream and unique applications? Our partners at ABX will have you up and running quickly.


Are you a pharmaceutical company or distribution network interested obtaining FAPI for your projects and patients? We are eager to learn more about how our compounds can facilitate your needs. Contact us today.



SOFIE has selected an automated radiosynthesizer for standardized production of its Ga-68 FAPI and F-18 FAPI. This will facilitate production at SOFIE’s facilities for supply to its clinical trial sites.


US-based FAPI-46 and FAPI-74 Tox studies have been completed by Covance at its Indianapolis facility.


ABX is SOFIE’s partner of choice for our FAPI precursor production. ABX has successfully completed the manufacture and shipment of the first stocks of FAPI precursor material, enabling our distribution of precursor and reference standards under MTAs to multiple approved users in the US and EU.

FAPI is not currently approved for general clinical use and should therefore be utilized in accordance with established regulatory guidelines in each jurisdiction.


Uwe Haberkorn, MD, PhD

Uwe Haberkorn, MD, PhD

  • Inventor of the FAPI theranostic family
  • Chair of the Department of Nuclear Medicine at the University of Heidelberg
  • Head of the Clinical Cooperation Unit of Nuclear Medicine at the DKFZ
Stefano Fanti, MD

Stefano Fanti, MD

  • Chairman of FAPI Scientific Advisory Board
  • Head of Nuclear Medicine, University of Bologna
Frederick Giesel MD, MBA

 Frederick Giesel, MD, MBA

  • Vice Chair of Nuclear Medicine, Department of Nuclear Medicine, University Hospital Heidelberg
  • Full Professor at Osaka University, Osaka Japan and expert in the field oncological theranostics
Clemens Kratochwil, MD

 Clemens Kratochwil, MD

  • Attending and Director, Therapy Unit, Department of Nuclear Medicine at the University of Heidelberg
Jens Siveke, MD

 Jens Siveke, MD

  • Head of the Division of Solid Tumor Translational Oncology (DKFZ/DKTK partner site Essen)
  • Full Professor in the Department of Medical Oncology at the West German Cancer Center, University Hospital Essen
Johannes Czernin, MD

Johannes Czernin, MD

  • Nuclear Medicine and Internal Medicine
  • Chief, Ahmanson Translational Imaging Division at UCLA
Ken Herrmann, MD, MBA

Ken Herrmann, MD, MBA

  • Chair of Nuclear Medicine at the University of Duisburg-Essen


Are you a pharmaceutical company or distribution network interested obtaining FAPI for your projects and patients? We are eager to learn more about how our compounds can facilitate your needs.

Go to Top